Palbace 75mg

Palbace 75mg is a prescription medication used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is a CDK4 and CDK6 inhibitor that works by targeting the cell cycle and inhibiting the growth of cancer cells.

Composition:

• Palbociclib 75mg

Mechanism of Action:

Palbociclib works by:

1. Inhibiting the activity of CDK4 and CDK6, which are proteins that regulate the cell cycle
2. Blocking the progression of the cell cycle from G1 to S phase, thereby preventing cancer cells from dividing and growing
3. Reducing the expression of genes that promote cancer cell growth and survival

Indications:

Palbace 75mg is approved for the treatment of:

• HR+, HER2- breast cancer in combination with letrozole in postmenopausal women with estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) breast cancer
• HR+, HER2- breast cancer in combination with fulvestrant in postmenopausal women with ER+ and PR+ breast cancer who have progressed on prior endocrine therapy

Dosage:

The recommended dosage of Palbace 75mg is:

• 75mg administered orally once daily for at least 21 days in a 28-day cycle
• The recommended duration of treatment is until disease progression or unacceptable toxicity occurs

Side Effects:

Common side effects of Palbace 75mg include:

1. Fatigue
2. Nausea and vomiting
3. Decreased neutrophil count
4. Decreased white blood cell count
5. Increased risk of infections
6. Diarrhea
7. Abdominal pain
8. Headache
9. Dizziness
10. Increased risk of bleeding

Recommendation:

Palbace 75mg is recommended for patients with HR+, HER2- breast cancer who have not responded to other treatments or who have progressed on prior endocrine therapy.

Important Note:

• Patients taking Palbace 75mg should be closely monitored for signs of infection, such as fever, chills, or swelling.
• Patients taking Palbace 75mg should avoid taking medications that may interact with it, such as warfarin or phenytoin.
• Pregnant or breastfeeding women should not use Palbace 75mg, as it may harm the fetus or infant.
• Regular follow-up appointments with your healthcare provider are necessary to monitor the effectiveness of Palbace 75mg and to detect any potential side effects or complications.

Special Precautions:

• Patients with a history of liver disease or liver dysfunction should be closely monitored while taking Palbace 75mg.
• Patients with a history of bleeding disorders should be closely monitored while taking Palbace 75mg.

Contraindications:

• Patients who are allergic to palbociclib or any other component of Palbace 75mg should not use it.
• Patients who are pregnant or breastfeeding should not use Palbace 75mg.
• Patients with severe liver disease or liver failure should not use Palbace 75mg.

Warnings:

• Palbace 75mg can cause severe neutropenia, which can increase the risk of infections.
• Patients with a history of neutropenia or bone marrow disorders should be closely monitored while taking Palbace 75mg.
• Patients should report any changes in their white blood cell count or symptoms of infection to their healthcare provider immediately.